J.P. Morgan Chase increased its holdings in Innovent Biologics (01801) by approximately 1.2337 million shares at a price of around HK$78.7 per share.
The latest information from the Hong Kong Stock Exchange shows that on February 2, Morgan Stanley increased its holding of Sino Biopharmaceutical (01801) by 1,233,667 shares, at a price of 78.6975 Hong Kong dollars per share, totaling approximately 97.08 million Hong Kong dollars.
According to the latest data from the Hong Kong Stock Exchange, on February 2nd, Morgan Stanley increased its holdings of INNOVENT BIO (01801) by 1,233,667 shares, at a price of 78.6975 Hong Kong dollars per share, with a total amount of approximately 97.0865 million Hong Kong dollars. After the increase, the latest number of shares held is approximately 87.9149 million shares, and the latest shareholding percentage is 5.06%.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
